Search > Myeloid Leukemia
120 Participants NeededMy employer runs this trial

CBX-663 for Cancer

(TelOscope Trial)

Recruiting at 3 trial locations
Age: 18+
Sex: Any
Trial Phase: Phase 1
Sponsor: Crossbow Therapeutics, Inc.
Must not be taking: Anti-VEGF, Anti-VEGFR
Disqualifiers: HIV, Hepatitis B, Hepatitis C, others
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

This is a Phase 1, open-label, dose-escalation study of CBX-663 in participants with R/R AML, MDS or CMML (Cohort A), advanced solid tumors (Cohort B), or recurrent or progressive GBM (Cohort C) (collectively called 'indication cohorts'). Participants aged ≥18 years are planned to be enrolled. CBX-663 will initially be investigated on a fixed dosing schedule. CBX-663 will be administered intravenously (IV) on Cycle 1 Day 1 (C1D1) and then once weekly (QW) in 21-day cycles. Participants will continue treatment with CBX-663 until unacceptable toxicity, progressive disease, withdrawal of consent, or lack of clinical benefit.

Are You a Good Fit for This Trial?

This trial is for adults (18+) with certain blood cancers (like relapsed or hard-to-treat myeloid leukemia), advanced solid tumors, or brain cancer (glioblastoma) that has come back or gotten worse after previous treatments.

Inclusion Criteria

I have relapsed or refractory MDS with less than 20% blasts and no remaining treatment options.
My high-risk MDS did not respond to or I could not tolerate hypomethylating agents.
My side effects from previous treatments are mild or only moderate hair loss remains.
See 24 more

Exclusion Criteria

I have not had another cancer in the past 2 years, except some treated skin cancers.
I have or may have leptomeningeal disease found by MRI or spinal fluid tests.
Cohort C: Absolute lymphocyte count <800/uL
See 22 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive CBX-663 intravenously on Cycle 1 Day 1 and then once weekly in 21-day cycles until unacceptable toxicity, progressive disease, withdrawal of consent, or lack of clinical benefit

Approximately 24 months

Follow-up

Participants are monitored for safety and effectiveness after treatment

30 days following end of treatment

What Are the Treatments Tested in This Trial?

Interventions

  • CBX-663

Trial Overview

The study is testing different doses of a new drug called CBX-663, given by IV once a week in repeating cycles. The main goal is to find out if the drug is safe and what dose works best for people with these tough-to-treat cancers.

How Is the Trial Designed?

1

Treatment groups

Experimental Treatment

Group I: CBX-663Experimental Treatment1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

Crossbow Therapeutics, Inc.

Lead Sponsor

Unbiased Results

We believe in providing patients with all the options.

Your Data Stays Your Data

We only share your information with the clinical trials you're trying to access.

Verified Trials Only

All of our trials are run by licensed doctors, researchers, and healthcare companies.